<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>AMA Publishing Group: Facial Rejuvenation - Nonsurgical Topic Collection</title>
    <link>http://pubs.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Thu, 21 Feb 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Thu, 21 Feb 2013 15:45:09 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@pubs.jamanetwork.com</managingEditor>
    <webMaster>webmaster@pubs.jamanetwork.com</webMaster>
    <item>
      <title>Electromyographic Differences Between Normal Upper and Lower Facial Muscles and the Influence of Onabotulinum Toxin A EMG Differences in Onabotulinum Toxin Treatment </title>
      <link>http://pubs.jamanetwork.com/article.aspx?articleID=1655116</link>
      <pubDate>Thu, 21 Feb 2013 00:00:00 GMT</pubDate>
      <author>Winn BJ, Sires BS. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Importance&lt;/div&gt;Empirically determined doses of onabotulinum toxin A for aesthetic treatments are as much as 5 times higher for the upper than for the lower facial muscles.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To use electromyography (EMG) to determine objectively whether the disparity between doses is due to intrinsic differences between the muscle groups' responses to onabotulinum toxin A or to variable amounts of paralysis required to achieve the desired aesthetic outcomes.&lt;div class="boxTitle"&gt;Design&lt;/div&gt;We collected EMG data before and at 2 to 4 weeks and 3 months after 8- and 2-U onabotulinum toxin A injections to the corrugator and depressor anguli oris muscles, respectively.&lt;div class="boxTitle"&gt;Setting&lt;/div&gt;A private oculofacial plastic surgery practice.&lt;div class="boxTitle"&gt;Participants&lt;/div&gt;Twenty-six subjects recruited from February 1 through April 1, 2009.&lt;div class="boxTitle"&gt;Interventions&lt;/div&gt;Electromyography recordings and cosmetic onabotulinum toxin A injections.&lt;div class="boxTitle"&gt;Main Outcome Measures&lt;/div&gt;Mean motor unit (MU) durations and maximal amplitudes at baseline and 2 to 4 weeks and 3 months after injection.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;Baseline mean MU amplitudes were similar for the corrugator and depressor anguli oris muscles. At 2 to 4 weeks after injection, 78% MU and 64% maximal amplitude reduction for the corrugator muscle were detected, but only 54% MU and 18% maximal amplitude reduction for the depressor anguli oris (P = 2.7 × 10&lt;sup&gt;−8&lt;/sup&gt; and P = 1.3 × 10&lt;sup&gt;−14&lt;/sup&gt;, respectively). At 3 months, function was partially recovered for both muscle groups.&lt;div class="boxTitle"&gt;Conclusions and Relevance&lt;/div&gt;Onabotulinum toxin A causes a similar dose-dependent reduction in MU and maximal voluntary amplitudes for muscles of the upper and lower face. The dose disparity appears to result from differences in the amount of paralysis required to achieve desirable aesthetic results.&lt;div class="boxTitle"&gt;Level of Evidence&lt;/div&gt;4. http://archfaci.jamanetwork.com/public/instructionsForAuthors.aspx#SecLevelofEvidence&lt;/span&gt;</description>
      <prism:startingPage xmlns:prism="prism">1</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">7</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jamafacial.2013.692</prism:doi>
      <guid>http://pubs.jamanetwork.com/article.aspx?articleID=1655116</guid>
    </item>
  </channel>
</rss>